The burgeoning landscape of treatment for weight management and type 2 glucose intolerance is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant differences in their pharmacological profiles and clinical investigation results are eme

Showing promise in the landscape of weight management management, retatrutide is a unique approach. Unlike many current medications, retatrutide functions as a twin agonist, simultaneously affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. This simultaneous engagement fosters several advantageous